Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. March 27, 2019. Boris Schmidt.

Executive Summary

CardioFocus' HeartLight X3 endoscopic laser ablation system recently won a CE mark based on results of a 60-patient trial showing the device consistently achieves pulmonary vein isolation in as few as three minutes for a single vein, among other accomplishments. See what primary investigator Boris Schmidt from Cardioangiologisches Centrum Bethanien said about the HeartLight X3 here.

"Our clinical results using the HeartLight X3 System have been outstanding, with unprecedented treatment speed and precise lesion creation. Based on our experience with the device, we feel confident that the HeartLight X3 System is poised to change the way AFib ablation is performed in Europe." –Boris Schmidt, primary investigator, Cardioangiologisches Centrum Bethanien

Click here for a free trial of Medtech Insight

 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel